Evidence map›Paper›PMID 36685545›Full record

ArticleFrontiers in immunology2022

The challenges of

Wanlapa Roobsoong, Anjali Yadava, Simon J Draper, Angela M Minassian, Jetsumon Sattabongkot

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wanlapa RoobsoongMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Anjali YadavaBiologics Research & Development, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Simon J DraperDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.
Angela M MinassianDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Funding

Medical Research Council G1100086Medical Research Council MC_PC_16056Wellcome Trust 212336/Z/18/Z
6 · The paper itself

Abstract

Controlled Human Malaria Infection models (CHMI) have been critical to advancing new vaccines for malaria. Stringent and safe preparation of a challenge agent is key to the success of any CHMI. Difficulty producing the

Indexed as

MalariaMalaria, VivaxParasitesVaccinesAnimalsHumansPlasmodium vivaxVaccine DevelopmentVaccinesCHMIcontrolled human malaria infectionmalaria human challenge studyMalaria Infection Study ThailandMISTPlasmodium vivax in vitro cultureP. vivax vaccine

Identifiers

PMID36685545
PMCPMC9849360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.